- Home
- CMBM vs SCYX Comparison
CMBM vs SCYX Comparison
Compare CMBM & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMBM
- SCYX
- Stock Information
- Founded
- CMBM 2011
- SCYX 1999
- Country
- CMBM United States
- SCYX United States
- Employees
- CMBM N/A
- SCYX N/A
- Industry
- CMBM Radio And Television Broadcasting And Communications Equipment
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- CMBM Technology
- SCYX Health Care
- Exchange
- CMBM Nasdaq
- SCYX Nasdaq
- Market Cap
- CMBM 50.8M
- SCYX 50.3M
- IPO Year
- CMBM 2019
- SCYX 2014
- Fundamental
- Price
- CMBM $1.16
- SCYX $1.20
- Analyst Decision
- CMBM Strong Buy
- SCYX Buy
- Analyst Count
- CMBM 3
- SCYX 1
- Target Price
- CMBM $5.50
- SCYX N/A
- AVG Volume (30 Days)
- CMBM 91.4K
- SCYX 185.1K
- Earning Date
- CMBM 11-07-2024
- SCYX 11-06-2024
- Dividend Yield
- CMBM N/A
- SCYX N/A
- EPS Growth
- CMBM N/A
- SCYX N/A
- EPS
- CMBM N/A
- SCYX N/A
- Revenue
- CMBM $172,215,000.00
- SCYX $8,566,000.00
- Revenue This Year
- CMBM N/A
- SCYX N/A
- Revenue Next Year
- CMBM $18.55
- SCYX $145.59
- P/E Ratio
- CMBM N/A
- SCYX N/A
- Revenue Growth
- CMBM N/A
- SCYX N/A
- 52 Week Low
- CMBM $1.08
- SCYX $1.19
- 52 Week High
- CMBM $6.50
- SCYX $3.07
- Technical
- Relative Strength Index (RSI)
- CMBM 38.76
- SCYX 29.63
- Support Level
- CMBM $1.12
- SCYX $1.25
- Resistance Level
- CMBM $1.29
- SCYX $1.37
- Average True Range (ATR)
- CMBM 0.10
- SCYX 0.07
- MACD
- CMBM 0.00
- SCYX -0.01
- Stochastic Oscillator
- CMBM 10.53
- SCYX 4.17
About CMBM Cambium Networks Corporation
Cambium Networks Corp provides wireless broadband networking infrastructure solutions for network operators, including medium-sized wireless Internet service providers, enterprises, and government agencies. The company geographically operates in North America; Europe, Middle East and Africa; Caribbean and Latin America; and Asia Pacific. It derives maximum revenue from North America.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.